Australian medical device company OncoSil Medical said the German Institute for the Hospital Remuneration System granted authorisation to 84 hospitals to negotiate funding for the OncoSil device under the new methods of treatment program.

The authorisation follows the "Positive Status 1" classification awarded in 2021, indicating a growing demand for innovative cancer treatment.

The approval is a significant step for OncoSil in Germany, potentially leading to systematic funding and increased patient access to the therapy.

The funding mechanism is vital for hospitals to secure additional funding for new medical devices.